<DOC>
	<DOCNO>NCT00003815</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Randomized phase III trial study effectiveness chemotherapy radiation therapy plus bone marrow transplantation treat patient aggressive non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy Plus Bone Marrow Transplantation Treating Patients With Aggressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Assess rate remission patient aggressive non-Hodgkin 's lymphoma treat high-dose chemotherapy radiotherapy plus autologous bone marrow transplantation . - Determine efficacy toxic effect regimen patient . OUTLINE : This randomize , placebo-controlled , multicenter study . Patients stratify accord risk group ( good v intermediate v poor ) . Patients undergo harvest autologous bone marrow stem cell prim chemotherapy transplantation . Patients receive induction chemotherapy comprise CHOP VAPEC-B regimen . The CHOP regimen consist vincristine ( VCR ) IV , cyclophosphamide ( CTX ) IV , doxorubicin ( DOX ) IV day 1 oral prednisolone ( PRDL ) day 1-5 . Treatment repeat every 3 week six course . The VAPEC-B regimen consist DOX IV day 1 , 15 , 29 , 43 , 57 , 71 ; CTX IV day 1 , 29 , 57 ; VCR IV day 8 , 22 , 36 , 50 , 64 ; bleomycin IV day 8 , 36 , 64 ; oral etoposide ( VP-16 ) day 15-19 , 43-47 , 71-75 ; oral PRDL daily 13 week . Patients may undergo radiotherapy 2-3 week area original bulk residual disease . - Good-risk group : Patients randomize one two treatment arm . - Arm I : Patients receive treatment . - Arm II : Patients receive melphalan ( L-PAM ) total body irradiation ( TBI ) , deliver 3 fraction 24 hour . After completion radiotherapy , patient undergo autologous bone marrow transplantation ( AuBMT ) . - Intermediate- poor-risk group : Patients randomize one three treatment arm . - Arm III : Patients receive L-PAM IV day -2 AuBMT day 0 . - Arm IV : Patients receive treatment arm II . - Arm V : Patients receive carmustine IV day -6 , VP-16 IV daily cytarabine IV twice daily day -5 -2 , L-PAM IV day -1 . Radiotherapy bulk disease begin completion chemotherapy . Patients undergo AuBMT day 0 . Patients follow monthly 3 month , every 2 month 1 year , every 4 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive nonHodgkin 's lymphoma require chemotherapy Stage II , III , IV B cell : Centroblastic Immunoblastic Large cell anaplastic NonBurkitt lymphoblastic T cell : Pleomorphic medium cell Pleomorphic large cell Immunoblastic Large cell anaplastic Lymphoblastic No Burkitt ( L3 ) subtype No large mediastinal mass OR Stage I , II , III , IV Bulk disease great 10 cm Nodal extranodal site No primary localize gut lymphoma No CNS involvement PATIENT CHARACTERISTICS : Age : 15 65 Performance status : Not specify Life expectancy : Not specify Hematopoietic : No concurrent bone marrow dysplastic syndrome Hepatic : Bilirubin great 2.5 time upper limit normal ( ULN ) Renal : Creatinine great 2.5 time ULN Other : No malignancy except skin cancer stage I cervical cancer Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2001</verification_date>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
</DOC>